Arrowhead Reports First Clinical Validation Of TRiM Platform As ARO-MAPT Achieves Up To 73% Mean and 85% Maximum Tau Reduction
Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on
Arrowhead's new medicine delivery system worked in human tests. This shows the company can get brain medicines to work better than before.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.